Welcome to our dedicated page for Endra Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on Endra Life Sciences stock.
ENDRA Life Sciences Inc. reports developments in thermoacoustic biomarker imaging, including its TAEUS® Liver device for measuring liver fat in steatotic liver disease, MASLD and MASH. Company news commonly covers clinical feasibility work comparing TAEUS measurements with MRI-PDFF, device repeatability and reproducibility, and business updates tied to operating results.
NDRA updates also include capital and treasury actions, such as private placement financing and a digital asset treasury strategy involving HYPE token holdings and staking. Corporate news has included strategic-review announcements and Nasdaq listing-compliance matters.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will release its fourth quarter 2021 financial results on March 30, 2022, after U.S. markets close. A conference call and webcast will follow at 4:30 p.m. Eastern time, covering the results and recent corporate developments. Interested participants are encouraged to pre-register for the call or can join via specific dial-in numbers. The company is known for its innovative Thermo Acoustic Enhanced UltraSound (TAEUS®) technology aimed at liver health assessments, which could revolutionize diagnostic practices for chronic liver diseases.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced participation in two investor conferences in March. The company will attend the 34th Annual ROTH Conference from March 13-15, 2022, where management will be available for one-on-one meetings on March 14 and a pre-recorded presentation will be posted online. Additionally, ENDRA will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 15 at 2:40 p.m. ET and offer virtual one-on-one meetings. ENDRA is known for its TAEUS® technology for liver health assessment.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has been granted U.S. Patent No. 11266314, which protects its TAEUS technology's method for determining material types. This patent enhances ENDRA's intellectual property strategy, potentially expanding applications beyond liver measurements and into broader clinical and non-clinical spheres. Currently, the company holds 89 intellectual property assets globally. ENDRA aims to revolutionize diagnostic imaging at lower costs, particularly addressing chronic liver conditions affecting over one billion people.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has received two new patents from the European Patent Office, enhancing its intellectual property portfolio. The patents include: European Patent No. 3668382, which safeguards a method for estimating fat content using a single thermoacoustic measurement, and European Patent No. 3661416, which protects a method using multiple measurements. These developments aim to advance ENDRA's TAEUS® technology, targeting clinical needs in liver disease assessment, and expand its existing portfolio of 89 patents.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has announced a strategic shift in its regulatory approach for the TAEUS System, designed to assess fatty liver tissue, now pursuing the De Novo pathway instead of a 510(k) application. This decision follows constructive discussions with the FDA, aiming for enhanced market claims. The De Novo process allows for a unique product classification, setting a higher standard for the TAEUS System. The company plans to withdraw its current 510(k) application and focus on limited confirmatory clinical data needed for the De Novo submission, expected to foster competitive advantages.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has received Institutional Review Board approval for a clinical study of its Thermo Acoustic Enhanced UltraSound (TAEUS) device at Shanghai General Hospital, targeting Non-Alcoholic Fatty Liver Disease (NAFLD). This marks ENDRA's first clinical research partnership in Asia, offering strategic entry into China's vast healthcare market, which serves 1.4 billion people. The study will compare TAEUS against MRI-PDFF in 75 patients, enhancing clinical evidence for commercialization.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will present a company overview at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 a.m. Eastern Time on ENDRA's website. ENDRA is known for its innovative technology, Thermo Acoustic Enhanced UltraSound (TAEUS®), which offers a cost-effective alternative to MRI for visualizing tissues, particularly for assessing liver conditions like NAFLD and NASH affecting over one billion people worldwide.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has partnered with King's College Hospital in London for a clinical study to assess the effectiveness of its TAEUS® ultrasound device in diagnosing Non-Alcoholic Fatty Liver Disease (NAFLD). This seventh clinical research partnership aims to compare TAEUS® with the standard MRI method, targeting 75 patients to enhance data diversity. The study will also provide clinical feedback to support ongoing commercialization of TAEUS®, which is already cleared for sale in Europe and has a pending FDA application.
ENDRA Life Sciences (NASDAQ: NDRA) has signed a collaboration agreement with VGI Health Technology to incorporate its TAEUS technology in VGI's upcoming Phase 2 study of IVB001 for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). This partnership aims to enhance patient screening and biomarker measurement, offering potential cost savings and efficiencies in clinical trial execution. VGI highlights the importance of capturing hepatic steatosis data to improve understanding of NAFLD-NASH, furthering their innovative approach in addressing these conditions.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced the issuance of two new patents by the U.S. Patent and Trademark Office. The patents include U.S. Patent No. 11172829, which enhances thermoacoustic imaging by reducing false signals, and U.S. Patent No. 11176848, which allows for a single phantom for multiple imaging modalities. These patents, the 22nd and 23rd for ENDRA, support the company's strategy to expand the applications of its TAEUS® technology, designed to assess liver conditions affecting over one billion people worldwide.